Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need.
News
From Target to Translation: Revealing the Mechanism Behind HIF-2α Inhibition in Kidney Cancer
A look at how ARC-20 connected tumor biology, blood-based biomarkers and clinical outcomes for casdatifan in kidney cancer.
Read more
Report
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
Read more
Report
Combining for Change in Kidney Cancer
While there has been substantial progress in treatment in recent years, even more innovative approaches are needed to improve survival, especially when the cancer is metastatic, meaning it has spread to other parts of the body.
Read more
Report
From Paper to Pill
There is opportunity to develop new and potentially improved molecules that block HIF-2α to further improve outcomes.
Read more
Report
Addressing Adenosine: Immunotherapy in the Tumor Microenvironment
Targeting the adenosine axis - components that contribute to the production of adenosine and its subsequent impact - is a promising option.
Read more
Report
Pro access
Upgrade to see all 11 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Growth
Hiring Momentum
53/100
Stable
Open positions
0
1 opened / 0 closed in 30 days
Hiring Dynamics
0%
